Our Why

“We are leveraging our cutting-edge science to develop lifesaving and life altering therapies for patients with rare immunological diseases.”

Søren Tulstrup, President and CEO

Latest news

May 23, 2022

Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation

May 13, 2022

Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix[®] (imlifidase) in kidney transplantation

Apr 21, 2022

Regulatory press release
Hansa Biopharma interim report January – March 2022

Stockholm
...
(...%)

HNSA ... SEK

Annual report 2021	EN	SE
Latest Financial Report	EN	SE

Events & Webcasts

30Jun

Annual General Meeting 2022

12Jul

William Blair’s Biotech Focus Conference 2022

New York

21Jul

Half year 2022 report

Introduction to Hansa

Søren Tulstrup, President & CEO

Join Hansa

From our headquarters in Lund, Sweden, we reach around the world. Our dedicated team includes experienced and courageous specialists driven by our purpose to develop lifesaving and life altering therapies for patients living with rare immunological diseases.

Since our founding in 2007, we have worked in cross functional and agile teams. We are gender-balanced, representing a vast number of nationalities and see diversity as an enabler for reaching our corporate objectives. The recruitment of highly motivated, experienced and talented team players supports our development towards a fully integrated global biopharmaceutical company.

In 2020 and 2021, Hansa Biopharma AB was certified as A Great Place to Work company by the independent institute Great Place to Work^® , a global authority on workplace culture, employee experience and leadership behaviour. We are immensely proud.

Careers